Search results
Results from the WOW.Com Content Network
(Although, in some cases, rotation of the injection sites may not be enough to prevent lipodystrophy.) [citation needed] Some of the side-effects of lipodystrophy are the rejection of the injected medication, the slowing down of the absorption of the medication, or trauma which can cause bleeding that, in turn, causes rejection of the medication.
Insulin resistance is when your tissues no longer adequately respond to insulin to lower blood glucose levels. Glucose is the sugar molecule your body uses for energy. Insulin is produced by beta ...
Localized lipodystrophy is a skin condition characterized by the loss of subcutaneous fat localized to sites of insulin injection. [1]: ...
Lipoatrophy is the term describing the localized loss of fat tissue.This may occur as a result of subcutaneous injections of insulin in the treatment of diabetes, from the use of human growth hormone or from subcutaneous injections of copaxone used for the treatment of multiple sclerosis.
The exact cause of lipodermatosclerosis is unknown. [3] [6] Venous disease, such as venous incompetence, venous hypertension, and body mass may be relevant to the underlying pathogenesis. [3] Increased blood pressure in the veins (venous hypertension) can cause diffusion of substances, including fibrin, out of capillaries.
Acquired generalized lipodystrophy (AGL), also known as Lawrence syndrome [1] and Lawrence–Seip syndrome, [1] is a rare skin condition that appears during childhood or adolescence, characterized by fat loss affecting large areas of the body, particularly the face, arms, and legs.
Familial Partial Lipodystrophy, Dunnigan Type Autosomal dominant is the manner of inheritance of this condition Dunnigan-type familial partial lipodystrophy , also known as FPLD Type II and abbreviated as ( FPLD2 ), is a rare monogenic form of insulin resistance characterized by loss of subcutaneous fat from the extremities , trunk , and ...
Familial partial lipodystrophy, also known as Köbberling–Dunnigan syndrome, [2] is a rare genetic metabolic condition characterized by the loss of subcutaneous fat. [ 3 ] : 495 FPL also refers to a rare metabolic condition in which there is a loss of subcutaneous fat in the arms, legs and lower torso.